AstraZeneca plc (NASDAQ: AZN)

AstraZeneca has transformed from a mid-tier pharma company into one of the industry's fastest growers, with revenue exceeding $46 billion. The Anglo-Swedish company has blockbusters across oncology (Tagrisso, Enhertu, Imfinzi), cardiovascular/metabolic (Farxiga), and rare diseases (Alexion portfolio). CEO Pascal Soriot's tenure since 2012 has been one of the most successful leadership runs in pharma history. AstraZeneca's COVID vaccine, developed with Oxford University, was distributed to over 180 countries.

Innovative pharmaceuticals across oncology (the largest segment at ~40% of revenue), cardiovascular/renal/metabolic, respiratory/immunology, and rare diseases (via the $39 billion Alexion acquisition in 2021). The company has been growing revenue at double-digit rates — unusual for a company of this size. Geographic diversification is strong, with significant presence in the U.S., Europe, China, and emerging markets.

AstraZeneca was formed in 1999 from the merger of Sweden's Astra AB and the UK's Zeneca Group. Pfizer attempted a hostile takeover in 2014 for $118 billion — Soriot fought it off, and the decision to remain independent looks brilliant in hindsight. The Alexion acquisition in 2021 added rare disease capabilities. The Oxford-AstraZeneca COVID vaccine was provided at cost during the pandemic, generating goodwill but minimal profit.